Fate Therapeutics, Inc. (FATE)
FATE Stock Price Chart
Explore Fate Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze FATE price movements and trends.
FATE Company Profile
Discover essential business fundamentals and corporate details for Fate Therapeutics, Inc. (FATE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
1 Oct 2013
Employees
181.00
Website
https://www.fatetherapeutics.comCEO
Bahram Valamehr
Description
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.
FATE Financial Timeline
Browse a chronological timeline of Fate Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.28, while revenue estimate is $1.37m.
Earnings released on 13 May 2026
EPS came in at -$0.26 surpassing the estimated -$0.29 by +10.34%, while revenue for the quarter reached $1.30m , missing expectations by -12.93%.
Earnings released on 26 Feb 2026
EPS came in at -$0.27 matching the estimated -$0.27, while revenue for the quarter reached $1.37m , beating expectations by +2.42%.
Earnings released on 13 Nov 2025
EPS came in at -$0.27 surpassing the estimated -$0.29 by +6.90%, while revenue for the quarter reached $1.74m , beating expectations by +45.31%.
Earnings released on 12 Aug 2025
EPS came in at -$0.29 surpassing the estimated -$0.35 by +17.14%, while revenue for the quarter reached $1.91m , beating expectations by +65.98%.
Earnings released on 13 May 2025
EPS came in at -$0.32 surpassing the estimated -$0.39 by +17.95%, while revenue for the quarter reached $1.63m , beating expectations by +37.53%.
Earnings released on 5 Mar 2025
EPS came in at -$0.31 surpassing the estimated -$0.44 by +29.55%, while revenue for the quarter reached $1.86m , beating expectations by +18.57%.
Earnings released on 12 Nov 2024
EPS came in at -$0.40 surpassing the estimated -$0.42 by +4.76%, while revenue for the quarter reached $3.07m , beating expectations by +132.88%.
Earnings released on 13 Aug 2024
EPS came in at -$0.33 surpassing the estimated -$0.47 by +29.79%, while revenue for the quarter reached $6.77m , beating expectations by +380.28%.
Earnings released on 9 May 2024
EPS came in at -$0.47 matching the estimated -$0.47, while revenue for the quarter reached $1.93m , beating expectations by +73.42%.
Earnings released on 26 Feb 2024
EPS came in at -$0.45 surpassing the estimated -$0.57 by +21.05%, while revenue for the quarter reached $1.68m , beating expectations by +5.41%.
Earnings released on 8 Nov 2023
EPS came in at -$0.46 surpassing the estimated -$0.59 by +22.03%, while revenue for the quarter reached $1.94m , beating expectations by +18.54%.
Earnings released on 8 Aug 2023
EPS came in at -$0.54 surpassing the estimated -$0.58 by +6.90%, while revenue for the quarter reached $933.00k , missing expectations by -83.13%.
Earnings released on 3 May 2023
EPS came in at -$0.19 surpassing the estimated -$0.55 by +65.45%, while revenue for the quarter reached $58.98m , beating expectations by +66.14%.
Earnings released on 28 Feb 2023
EPS came in at -$0.58 surpassing the estimated -$0.86 by +32.56%, while revenue for the quarter reached $44.36m , beating expectations by +148.07%.
Earnings released on 3 Nov 2022
EPS came in at -$0.86 surpassing the estimated -$0.93 by +7.53%, while revenue for the quarter reached $14.98m , missing expectations by -1.96%.
Earnings released on 3 Aug 2022
EPS came in at -$0.79 surpassing the estimated -$0.86 by +8.14%, while revenue for the quarter reached $18.55m , beating expectations by +47.95%.
Earnings released on 4 May 2022
EPS came in at -$0.68 surpassing the estimated -$0.78 by +12.82%, while revenue for the quarter reached $18.41m , beating expectations by +104.34%.
Earnings released on 28 Feb 2022
EPS came in at -$0.72 falling short of the estimated -$0.68 by -5.88%, while revenue for the quarter reached $17.07m , beating expectations by +50.91%.
Earnings released on 4 Nov 2021
EPS came in at -$0.57 surpassing the estimated -$0.58 by +1.72%, while revenue for the quarter reached $14.23m , beating expectations by +80.29%.
Earnings released on 4 Aug 2021
EPS came in at -$0.58 falling short of the estimated -$0.52 by -11.54%, while revenue for the quarter reached $13.41m , meeting expectations.
FATE Stock Performance
Access detailed FATE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
